PS1 Phase 2 Trial Amendment Passes FDA IND 30-Day Review

PHARMASAGA (TPEx Emerging Stock Market: 7878) announced on MOPS that the trial amendment for PS1-II-201, its Phase 2 clinical trial of PS1 in type 2 diabetes, submitted to the U.S. FDA, has passed the FDA's 30-day IND review period. The company will continue to advance the PS1-II-201 trial.

Actual timelines will depend on FDA review and clinical trial progress, and further updates will be disclosed in accordance with regulations. Drug development is lengthy, capital-intensive, and not guaranteed to succeed.

Please refer to the official MOPS announcement for full details. 📌